Picture it:

Systemic treatment → travels through the body.

Local treatment → concentrates treatment on one tumour or one defined location.

Local treatment can destroy tumour tissue using heat, cold, electrical energy, mechanical energy or another focused method.

Whether it makes sense depends on tumour size, tumour position, number of disease sites, nearby structures, liver reserve, treatment goal and specialist expertise.

Ask: Which tumour are we trying to control, what is the local treatment trying to achieve, and what would successful control make possible next?

Local → one defined target.

Locoregional → tumour plus the organ or region around it.

In liver-directed treatment, the hepatic arterial system can be used as a route to deliver treatment into the region containing the cancer.

Examples include TACE, SIRT / Y-90 and hepatic arterial infusion chemotherapy.

Ask: Is this treatment aimed at one tumour, several tumours within part of the liver, or a wider region of disease?

Think of ablation as destroying the tumour in place.

Tumour identified → treatment focused into or around the tumour → physical energy damages tumour tissue → treated cells die → the body gradually processes the damaged tissue.

The technique matters because tumour size, tumour position, nearby blood vessels, bile ducts and other organs can affect which method is suitable.

Radiofrequency ablation and microwave ablation are recognised options for selected small intrahepatic tumours when surgery is not suitable.

Ask: Can my tumour be completely treated with ablation, which form is being considered, and what makes that method suitable for its size and position?

Imaging identifies tumour → probe enters target → electrical current produces heat → temperature rises → treated tumour tissue is destroyed.

Australian optimal-care guidance identifies RFA as a treatment that may be considered for selected intrahepatic biliary cancers no greater than 3 cm when surgery is contraindicated.

Tumour size is only part of the decision. Position, nearby blood vessels, bile ducts and other organs can also affect whether complete treatment can be achieved safely.

Ask: Is my tumour small enough and positioned so that RFA can safely treat the whole target?

Imaging identifies tumour → probe enters target → microwave energy agitates water molecules → temperature rises rapidly → treated tumour tissue is destroyed.

Australian optimal-care guidance identifies microwave ablation as a treatment that may be considered for selected intrahepatic biliary cancers no greater than 3 cm when surgery is contraindicated.

Ask: Why is microwave ablation being considered rather than RFA or another local treatment for my tumour?

Probe enters tumour → tissue freezes → ice forms within and around cells → cell structures are damaged → treated tumour tissue dies.

Cryoablation is not one of the specific thermal-ablation techniques highlighted in the Australian optimal-care pathway for biliary tract cancer.

Its role therefore depends more heavily on tumour anatomy, specialist expertise, available evidence and the wider treatment plan.

Ask: Why is cryoablation being considered for my tumour, and what advantage would freezing provide over a more established local option?

Picture the outer membrane of each cancer Cell City.

Needles positioned around tumour → electrical pulses pass between them → permanent microscopic openings form in cell membranes → cells lose control of their internal environment → treated tumour cells die.

Because its main effect is not produced by heat, IRE may be considered in selected situations where important blood vessels, bile ducts or other structures are close to the tumour.

IRE is not specifically identified as a standard biliary tract cancer locoregional treatment in the Australian optimal-care pathway.

Its use therefore requires an individual assessment of anatomy, evidence, specialist experience and treatment purpose.

Ask: What feature of my tumour's location makes IRE worth considering, and what would successful local control make possible next?

First, picture the tumour's blood supply

1. Finding the tumour's supply line

An interventional radiologist inserts a thin, flexible tube called a catheter into an artery, usually through the groin or wrist.

Using live X-ray imaging, the catheter is guided through the blood vessels to an artery feeding the tumour.

Think of this as finding the delivery road that carries supplies directly into the tumour.

2. Delivering chemotherapy locally

Chemotherapy is delivered through the catheter into the selected tumour-feeding artery.

The aim is to concentrate the medicine around the tumour, where it can damage cancer cells and interfere with their ability to survive and multiply.

Unlike systemic chemotherapy, which circulates throughout the body, TACE delivers treatment close to the intended target.

Some chemotherapy can still enter the wider circulation.

3. Reducing the tumour's blood supply

Next comes embolisation.

The specialist delivers material, often tiny particles or beads, to reduce blood flow through the selected artery.

Depending on the technique, chemotherapy and blocking material may be delivered together.

Think of the tumour's supply road being partially or substantially closed.

With its arterial blood supply reduced, the tumour receives less oxygen and fewer nutrients, while chemotherapy acts locally.

Together, these effects aim to damage or kill cancer cells and slow or reduce tumour growth.

Find the tumour-feeding artery → deliver chemotherapy locally → reduce arterial blood flow → damage cancer cells → assess tumour response.

What happens when both treatments work together?

Chemotherapy attacks cancer cells in the targeted area.

Embolisation reduces the arterial blood supply supporting those cells.

Together, they aim to control the selected tumour while limiting exposure elsewhere in the body.

TACE uses the tumour's arterial blood supply as both a treatment route and a target.

Why might I be offered TACE?

TACE may be considered for selected patients with cancer in the liver, including some patients with intrahepatic cholangiocarcinoma.

Its purpose may be to slow growth, reduce tumour activity or help control disease within the liver.

Suitability depends on tumour location and distribution, blood vessel anatomy, liver function, disease elsewhere and the overall treatment goal.

TACE is a local treatment. It does not automatically treat cancer outside the targeted area.

For some carefully selected patients, successful local control may create an opportunity for further treatment or surgical reassessment. This is not guaranteed.

What about the risks?

Pain, fever, nausea and tiredness can occur after treatment and often improve over several days.

More serious complications, including liver injury or infection, are possible.

Existing bile duct obstruction, biliary stents, previous biliary drainage or surgery may affect infection risk and treatment planning.

The treating team must assess whether enough healthy liver tissue can continue functioning safely after the procedure.

How will we know whether TACE worked?

Follow-up CT or MRI imaging is used to assess how much of the targeted tumour remains active, whether its size has changed and whether additional treatment is needed.

The timing and interpretation of these scans depend on the treatment plan.

Questions for your oncologist

1. What are we targeting? Which tumour or tumours will TACE treat, and will any known cancer remain outside the treatment area?

2. What are we trying to achieve? Is the objective to slow growth, shrink the tumour, control symptoms or create an opportunity for further treatment?

3. Why TACE? Why is TACE preferred over other liver-directed treatments, systemic therapy or clinical trials?

4. Is it safe for me? Is my liver function adequate, and do any bile duct problems, stents or previous procedures increase my risks?

5. How will success be measured? When will imaging be repeated, what result are we looking for, and who will decide what happens next?

6. What could success make possible? If TACE controls or reduces the tumour, will an experienced HPB surgical team reassess whether surgery or another treatment has become possible?

REMEMBER THIS

TACE delivers chemotherapy through the tumour's arterial supply and reduces that blood flow. The important question is not only whether it can control the tumour, but what successful control could make possible next.

Picture the liver's arterial system being used as a delivery route for radiation.

Catheter enters artery → catheter reaches the liver tumour supply → tiny Y-90 particles are released → particles lodge in small vessels around tumour tissue → radiation acts locally.

Y-90 delivers radiation from inside the tumour's arterial territory.

This is why the treatment is called selective internal radiation therapy, or SIRT.

Australian optimal-care guidance recognises SIRT as a locoregional option that may be considered in selected patients, including alongside systemic treatment, under multidisciplinary guidance.

Ask: Which part of my liver is being targeted, what is Y-90 trying to achieve, and why is it preferred over another local treatment in my case?

Picture the hepatic artery as a treatment route into the liver.

Catheter or infusion system accesses hepatic artery → chemotherapy enters arterial blood supplying the liver → high local treatment concentration reaches liver tumours.

HAIC is chemotherapy. What changes is the delivery route: treatment is directed into the liver rather than given only as ordinary whole-body intravenous chemotherapy.

Australian optimal-care guidance recognises HAIC alongside other intra-arterial locoregional approaches that may be considered under multidisciplinary guidance.

The decision still depends on disease distribution, liver function, anatomy, previous treatment, systemic disease and treatment purpose.

Ask: Why is HAIC being considered for me, which liver disease is it intended to control, and how does it fit with my systemic treatment plan?

Picture multiple ultrasound pulses being focused onto one precise target inside the tumour.

Ultrasound energy focused from outside body → pressure concentrates inside tumour → microscopic bubble cloud forms → bubbles rapidly expand and collapse → targeted tumour tissue is mechanically disrupted.

Histotripsy breaks apart targeted tissue without inserting an ablation probe into the tumour for the tissue destruction itself.

Histotripsy is not one of the established biliary tract cancer locoregional treatments identified in the Australian optimal-care pathway.

Its relevance therefore depends on tumour location, technical accessibility, specialist experience, evidence, treatment purpose and access.

Ask: Is my tumour technically accessible to histotripsy, what evidence supports using it in my situation, and what would successful local treatment make possible next?

Picture the chromosomes inside City Hall as Volumes of City Plans made from DNA.

Radiation reaches treatment area → energy is deposited in tissue → DNA is damaged → cancer cell attempts repair → enough unrepaired damage can stop division or lead to cell death.

Radiation is not one single technique.

It includes conventional external-beam radiation, stereotactic radiation, proton therapy and brachytherapy.

Australian consensus recognises radiation as a possible treatment in selected biliary tract cancer settings, including locally advanced disease, unresectable intrahepatic disease and some local recurrences.

Ask: What exactly are we targeting, what is radiation trying to achieve, and what would successful treatment make possible next?

Picture radiation being aimed from outside the body toward a three-dimensional target inside it.

Tumour mapped on imaging → radiation plan designed → beams enter body from selected directions → planned dose concentrates in target → nearby organs are kept within planned dose limits.

Australian consensus says EBRT can be considered for unresectable intrahepatic cholangiocarcinoma.

EBRT or chemoradiotherapy may also be considered as definitive treatment for selected locally advanced cholangiocarcinoma.

Ask: What area is included in my radiation field, what dose is planned, and which nearby organs limit that dose?

Think of a photon as a packet of electromagnetic energy.

Medical treatment machines produce high-energy X-ray photons and direct them toward the tumour.

Photon beam enters body → deposits energy on the way in → passes through tumour → damages tumour-cell DNA → some radiation continues beyond target.

Ask: What healthy organs are close to my tumour, and how is the photon plan protecting them?

Think of Gy as the measurement attached to the radiation dose.

One Gray means one joule of radiation energy has been absorbed per kilogram of tissue.

You do not need to calculate that yourself.

Gy tells you how much radiation dose the treatment plan is prescribing.

A higher Gy number does not automatically mean a better or stronger treatment.

The useful and safe dose depends on the tumour, treatment goal, number of fractions and healthy organs nearby.

Ask: What total dose am I receiving in Gy, and why is that dose appropriate for this tumour and treatment goal?

One radiation dose delivered at one treatment session is called a fraction.

Total planned radiation dose → divided into smaller doses → each dose is one fraction → fractions delivered over the planned schedule.

Fraction = one treatment dose.

Fractionation = the plan for how all those doses are divided.

Hypofractionation usually means fewer treatment sessions with a larger dose in each fraction.

Hyperfractionation means the total treatment is divided into more frequent, generally smaller fractions.

These words do not tell you whether a treatment is better or worse. They describe how the dose is scheduled.

Ask: How many fractions am I receiving, how much radiation is delivered in each fraction, and why was this schedule chosen?

Think of two treatments putting pressure on the same cancer in different ways.

Chemotherapy given → cancer cells may become more vulnerable to radiation → radiation damages DNA in treatment area → combined treatment increases local treatment pressure.

Australian consensus says chemoradiotherapy may be considered as definitive treatment for selected inoperable locally advanced cholangiocarcinoma.

It may also be considered following resection of margin-positive or node-positive intrahepatic cholangiocarcinoma.

For selected unresectable perihilar cholangiocarcinoma where liver transplantation is not an option, concurrent chemoradiation, with or without intraluminal brachytherapy, may be considered after an initial period of treatment.

Ask: Why are chemotherapy and radiation being combined in my case, and what advantage are we trying to gain compared with either treatment alone?

Picture several precisely aimed radiation paths meeting at one tumour.

Tumour mapped → movement and nearby organs measured → radiation paths planned from several directions → dose converges at target → concentrated treatment delivered over fewer fractions.

SBRT is not automatically suitable simply because a tumour can be seen.

Australian consensus specifically warns that strict organ dose limits are important when the target is on or near bowel or another luminal structure.

In selected unresectable perihilar disease, dose-reduced SBRT may be considered where chemotherapy is contraindicated.

Ask: Is my tumour safely positioned for SBRT, how many fractions are planned, which nearby organs limit the dose, and what result are we aiming for?

Despite the name, there is no knife.

CyberKnife is a radiation machine mounted on a robotic arm.

Tumour mapped → robotic arm moves around patient → radiation delivered from many directions → treatment beams concentrate at tumour.

CyberKnife is a way of delivering stereotactic radiation. It is not surgery.

Ask: Is CyberKnife being recommended because it offers a technical advantage for the location or movement of my tumour, or could another SBRT system achieve the same goal?

Picture an atom.

At its centre is a nucleus. Inside that nucleus are particles called protons and neutrons.

Proton therapy takes protons, accelerates them to very high speed and forms them into a treatment beam.

Protons accelerated → beam enters body → protons travel toward planned depth → much of treatment energy released around target → less radiation continues beyond tumour.

Conventional photon radiation continues depositing some energy as it passes beyond the target.

Proton therapy can reduce that exit dose.

That does not automatically make proton therapy better for every tumour.

Its value depends on tumour position, depth, surrounding anatomy and whether reducing radiation to nearby healthy tissue creates a meaningful treatment advantage.

Ask: What specific healthy organ or tissue would proton therapy protect better in my case, and would that difference meaningfully change treatment safety or effectiveness?

Picture bringing the radiation source close to the inside of the bile duct rather than aiming all treatment from outside.

Treatment catheter positioned → radiation source placed near target → radiation delivered over short distance → surrounding tumour receives concentrated dose.

Australian consensus says concurrent chemoradiation with or without intraluminal brachytherapy may be considered in selected unresectable perihilar cholangiocarcinoma when liver transplantation is not an option.

Ask: Why is intraluminal brachytherapy being considered, what part of the bile duct are we trying to treat, and what additional benefit is expected beyond external radiation?

Think of immunotherapy as changing the relationship between the immune system and the cancer.

Checkpoint immunotherapy does not directly kill cancer cells in the same way chemotherapy is designed to.

Instead, it changes immune control so an existing immune response may remain active against the cancer.

Cancer displays something recognisable → T cell recognises it → T cell becomes activated → checkpoint brake reduces activity → checkpoint medicine blocks that brake → immune attack may continue → cancer may be controlled.

Immunotherapy can release a brake. It cannot create every missing part of an immune response.

Protect the next opportunity before treatment starts.

If liver transplantation could still be a treatment option, checkpoint immunotherapy should be discussed with the transplant team before the first dose. Australian expert work identifies important concerns about checkpoint treatment before transplantation, including transplant rejection.

Ask: Which immunotherapy am I receiving, which checkpoint does it target, why does it fit my treatment setting, and could starting it affect any curative or transplant opportunity I may still have?

Picture a T cell as a mobile security unit.

It does not attack every cell.

Instead, it inspects small molecular samples displayed by cells for evidence that something may be infected, damaged or abnormal.

Proteins can be broken into small pieces called peptides.

These peptide samples are displayed by molecules called MHC for T cells to inspect.

An antigen is something the immune system can specifically recognise.

Protein is broken into peptide pieces → peptide is displayed by MHC → T cell inspects it → recognition may occur → activating and braking signals are weighed → immune action may follow.

Recognition tells the T cell what it is seeing. Other signals help determine whether it should act.

Ask: What is expected to make my cancer visible to T cells?

Picture each Cell City displaying small samples of what is being made inside it.

Inside City Hall, chromosomes are the Volumes of City Plans. Those volumes are made of DNA.

Genes are Chapters of City Instructions within those volumes.

If a DNA alteration changes one of those instructions, the resulting protein can also change.

Proteins can then be broken into small peptide fragments and displayed for immune inspection.

If an altered protein creates a new fragment the immune system has not previously recognised, that fragment may act as a neoantigen.

DNA alteration survives → gene instruction changes → altered protein is produced → peptide fragment is displayed → T cell may recognise something unusual → immune attack becomes possible.

Not every mutation creates a useful neoantigen. And not every neoantigen produces an effective immune response.

Cancers with large numbers of DNA copying errors can sometimes produce more abnormal protein fragments.

This helps explain why MSI-H, dMMR and high TMB can be relevant to immunotherapy.

Ask: Is there anything in my tumour biology suggesting the cancer may be particularly visible to the immune system?

Think of an APC as the immune system's briefing officer.

The APC collects material from around it or from cells it has encountered.

Proteins in that material are broken into small pieces called peptides.

The APC displays selected peptides on its surface.

A molecule called MHC holds each peptide up for inspection.

Peptide = the protein piece being displayed.

MHC = the holder displaying that piece.

APC = the immune cell doing the displaying.

A T cell can inspect the peptide being held by MHC.

But recognising the peptide is usually not enough to fully activate a naive T cell.

The APC can also provide another activating signal through molecules called B7.

B7 can connect with a receptor called CD28 on the T cell.

APC collects material → protein is broken into peptides → MHC displays peptide → T cell recognises it → B7 can connect with CD28 → activation signal strengthens → T cell may become fully activated.

The displayed peptide helps tell the T cell what it is seeing.

Additional signals help tell the T cell whether to act.

Important APCs include dendritic cells, macrophages and B cells.

Ask: Is the immune system only recognising the cancer, or is it also receiving the signals needed to activate an effective T-cell response?

Think of CD28 as a go receiver on the T cell.

A receptor is a protein that receives a signal from another molecule.

Before CD28 becomes important, the T cell has already inspected a peptide being displayed by an antigen-presenting cell.

Recognition is usually only the first signal.

The APC also carries signalling molecules called B7.

When B7 connects with CD28, the T cell receives an additional activating signal.

APC displays peptide → T cell recognises it → B7 connects with CD28 → additional go signal enters the T cell → activation strengthens.

This additional activating signal is called co-stimulation.

Recognition tells the T cell what it sees.

CD28 helps tell it to activate.

CD28 matters to the CTLA-4 pathway because CTLA-4 can also interact with B7 molecules.

CD28 helps strengthen activation.
CTLA-4 helps restrain activation.

Ask: What additional signal does the T cell need after recognising the antigen, and how does CD28 help provide it?

Think of B7 as the signalling partner displayed by the APC.

B7 is a family name. The two molecules most important here are CD80 and CD86.

B7 can connect with two different receptors on the T cell: CD28 and CTLA-4.

B7 connects with CD28 → activating signal strengthens.

B7 connects with CTLA-4 → braking influence increases.

APC = the cell presenting the signal.
B7 = the signalling partner on the APC.
CD28 = the activating receptor on the T cell.
CTLA-4 = the braking receptor on the T cell.

The biology is more complex than two simple switches, but this is the useful patient picture.

Ask: Is B7 interacting with CD28 to strengthen activation, or with CTLA-4 to increase braking?

Think of a checkpoint as a normal brake, not something invented by the cancer.

Immune attack can damage healthy tissue if it continues without control.

The body therefore uses biological control systems to restrain activated immune cells.

PD-1 and CTLA-4 are two important checkpoint systems.

The checkpoint is normal. Checkpoint treatment changes how strongly that brake can operate.

Ask: Which checkpoint is my treatment blocking: PD-1, PD-L1, CTLA-4 or another pathway?

Picture PD-1 as a brake receiver on the T cell.

The technical word for a receiving protein is a receptor.

PD-1 has two known binding partners: PD-L1 and PD-L2.

A molecule that binds to a receptor is called a ligand.

PD-L1 or PD-L2 connects with PD-1 → braking signal enters the T cell → T-cell activity falls → immune attack may weaken.

Pembrolizumab and nivolumab bind PD-1 and interfere with this braking pathway.

Receptor = the receiver.
Ligand = the molecule that binds to it.
PD-1 = the brake receiver.
PD-L1 and PD-L2 = ligands that can engage it.

Ask: Is my medicine blocking PD-1, and what are we trying to achieve by releasing that brake?

Think of PD-L1 as one of the molecules that can engage the PD-1 brake.

PD-L1 on a tumour or nearby cell → connects with PD-1 on a T cell → braking signal is sent → immune activity may decrease.

PD-L1 is the ligand. PD-1 is the receptor.

Durvalumab blocks PD-L1.

PD-L1 can also be measured on pathology testing, but its meaning depends on the cancer and treatment setting.

A low or negative PD-L1 result does not automatically mean checkpoint immunotherapy has no role.

In established first-line checkpoint combinations used in advanced biliary tract cancer, a positive PD-L1 result is not required simply to consider the regimen.

Picture a T cell receiving both a go signal and a brake signal.

First, the T cell recognises a peptide being displayed by an antigen-presenting cell.

Recognition alone is usually not enough to fully activate a naive T cell.

CD28 is an activating receptor on the T cell.

B7 molecules on the antigen-presenting cell can connect with CD28 and strengthen activation.

CTLA-4 is another receptor on the T cell.

It can also interact with B7, but its effect is to increase braking pressure on T-cell activation.

APC displays peptide → T cell recognises it → B7 can connect with CD28 → activation strengthens → CTLA-4 can also engage B7 → braking influence increases → T-cell activation is restrained.

CD28 helps strengthen activation.
CTLA-4 helps restrain activation.
Both interact with B7.

Ipilimumab blocks CTLA-4.

Reducing that braking influence can allow stronger T-cell activation.

The underlying biology is more complex than two simple switches, but this model preserves the central patient-level distinction: CD28 supports activation, while CTLA-4 helps limit it.

Ask: Why is CTLA-4 being targeted in my case, and what is it expected to add beyond PD-1 treatment alone?

Start with the brake, not the drug name.

Pembrolizumab → blocks PD-1.

Nivolumab → blocks PD-1.

Durvalumab → blocks PD-L1.

Ipilimumab → blocks CTLA-4.

Checkpoint inhibition is not generic immune stimulation. It is targeted interference with a specific immune brake.

Blocking one checkpoint does not remove every barrier between a T cell and the cancer.

The cancer may still be difficult to recognise, difficult to enter, biologically suppressive, or surrounded by T cells that have become exhausted.

Ask: Which checkpoint does my medicine block, why is that checkpoint relevant in my treatment setting, and what still has to be true for releasing that brake to help control my cancer?

Picture the tumour as a neighbourhood, not just a ball of cancer cells.

Cancer cells live among immune cells, blood vessels, support cells, connective tissue, signalling molecules, nutrients and metabolic waste.

Together, these conditions form the tumour microenvironment.

In cholangiocarcinoma, this environment can contain particularly dense fibrous support tissue.

The medical term for this is desmoplastic stroma.

The local environment can also become difficult for immune cells to work in.

Low oxygen, altered nutrient use, acidity and suppressive signalling can all reduce effective immune function.

Cancer continues growing → surrounding tissue and signalling change → immune cells encounter physical, chemical and metabolic barriers → T-cell function weakens → cancer survives → suppressive conditions continue.

Releasing one checkpoint brake does not remove every barrier inside the tumour microenvironment.

Ask: If checkpoint treatment is not controlling my cancer, could the problem involve more than the checkpoint itself, such as immune exclusion, suppressive tumour conditions or poor T-cell function?

Think of desmoplastic stroma as dense scaffolding built around the cancer.

A tumour is not made only of cancer cells.

It also contains support cells, blood vessels, connective tissue and other material surrounding those cells.

This supporting tissue is called stroma.

When the stroma becomes unusually dense and fibrous, it is called desmoplastic stroma.

Stroma = support tissue around the cancer.

Desmoplastic = unusually dense and fibrous.

Tumour develops → surrounding support tissue changes → dense stroma builds → movement and signalling inside the tumour change → immune cells and treatments may face a more difficult environment.

T cells may sometimes remain around a tumour but have difficulty entering the areas containing cancer cells.

This can contribute to what is called immune exclusion.

Immune exclusion = immune cells are present, but are having difficulty reaching the cancer cells they need to attack.

Dense stroma can also affect blood flow, chemical signalling and movement of medicines through the tumour.

It is not a simple wall, and it is not the only reason treatment may fail.

Ask: Could dense tumour stroma or immune exclusion be making it harder for T cells or treatment to reach my cancer effectively?

Think of a T cell being kept on the same emergency for too long.

Cancer can keep presenting recognised targets to the immune system over a long period.

That prolonged stimulation can gradually change how the T cell works.

An exhausted T cell may produce fewer attack signals, kill less effectively, and respond less strongly than it did before.

Exhausted T cells can also express more inhibitory control proteins.

PD-1 is one of those control proteins, but immune exhaustion is broader than PD-1 alone.

Cancer keeps presenting antigen → T cell keeps responding → prolonged stimulation changes the T cell → attack signals weaken → killing becomes less effective → cancer survives → stimulation continues.

PD-1 = one immune brake.

Immune exhaustion = a broader loss of T-cell function after prolonged stimulation.

Blocking PD-1 can sometimes restore useful T-cell activity.

But removing one brake may not fully restore a T cell that has become deeply exhausted.

Ask: If checkpoint treatment is not working, could the T cells be too exhausted or suppressed to respond effectively even after the brake is released?

Releasing an immune brake is only one step.

Cancer displays something recognisable → T cell recognises it → T cell becomes activated → T cell reaches the cancer → T cell remains functional → checkpoint brake is released → immune attack continues → cancer may be controlled.

Recognition = the T cell can see the target.

Access = the T cell can reach the cancer.

Function = the T cell can still act.

Checkpoint release = one brake is removed.

Response = the cancer is actually being controlled.

Cancer control may appear in different ways.

Tumours may shrink, remain stable, or stay controlled for a meaningful period without growing.

Response is usually assessed using scans, measurable tumour change, symptoms, overall condition, and how those findings change over time.

Immunotherapy response is not defined by receiving the medicine. It is defined by evidence that the cancer is being controlled.

Occasionally, immunotherapy can produce unusual early scan patterns.

One of these is called pseudoprogression.

But an enlarging tumour should not automatically be assumed to be pseudoprogression.

Ask: What will count as a response in my case, when will it be assessed, and what evidence would make us continue, change or stop treatment?

Think of resistance as the cancer finding another way to survive.

There are two broad patterns.

Primary resistance means immunotherapy never produces useful cancer control.

Acquired resistance means the cancer is controlled for a period and then begins growing again.

Primary resistance = it never worked well enough.

Acquired resistance = it worked first, then the cancer escaped.

Primary resistance can occur if one or more essential steps in the immune response are missing.

Cancer is not recognised well → T cells are not activated strongly → T cells cannot reach the cancer → T cells are exhausted or suppressed → the checkpoint being blocked is not the main barrier → useful cancer control does not develop.

Acquired resistance can develop because cancer cells are not all identical.

Treatment may control cancer cells that are easier for the immune system to attack, while harder-to-attack cells survive.

Cancer population varies → immune treatment controls more vulnerable cells → harder-to-attack cells survive → surviving population becomes more dominant → cancer begins growing again.

Cancer cells can also change how they are seen by the immune system.

They may lose a recognised antigen or alter the machinery used to display peptide fragments to T cells.

Antigen loss = the immune system loses a target it was recognising.

Altered antigen presentation = the target may still exist, but is no longer displayed effectively for T cells to inspect.

Resistance can also involve other immune brakes, immune exhaustion, dense tumour stroma, or other changes in the tumour microenvironment.

Releasing one immune brake does not guarantee every other barrier has been removed.

Ask: Is this primary or acquired resistance, what may have changed biologically, and does that create another treatment or clinical-trial opportunity?

Checkpoint treatment changes immune control, not just the cancer.

The aim is to help immune cells continue attacking the cancer.

But the same change can sometimes allow immune activity to affect healthy tissue.

Checkpoint brake reduced → immune activity changes → immune cells may attack cancer → healthy tissue may also be affected → inflammation or organ injury may develop.

Bowel → diarrhoea or colitis.

Lungs → pneumonitis.

Liver → hepatitis.

Skin → rash or inflammation.

Thyroid or other hormone glands → changes in hormone production.

Kidneys, nerves, muscles, heart and other organs can also be affected.

Immune-related adverse events can begin during treatment, after several treatment cycles, or sometimes after checkpoint treatment has stopped.

A new symptom does not automatically mean an immune-related adverse event.

Other causes are possible.

Important:

A new, worsening or unexplained symptom while receiving checkpoint immunotherapy should be reported promptly to the treating team. Do not wait for the next routine appointment if you are becoming unwell.

New symptom → report it → let the treatment team decide whether it could be immune-related.

Ask before treatment starts: Which symptoms should make me contact the treatment team immediately, who do I contact after hours, and what should I tell another doctor or emergency department about my checkpoint treatment?

Think of it as treatment with a question attached.

A trial may test a new drug, a new combination, a new way of delivering treatment, or whether an existing treatment works in a different group of patients.

Important: A clinical trial is not automatically better than established treatment, and benefit is never guaranteed.

Ask: What is the main question this trial is trying to answer, and why might the treatment be relevant to my cancer?

Think of the trial protocol as the rulebook for the whole study.

Before the trial opens, researchers decide exactly how the study will be run.

The protocol sets rules for things such as:

who can enter,
who cannot enter,
which treatment is given,
the dose and schedule,
which tests and scans are required,
how side effects are managed,
what counts as treatment success,
and when treatment must stop.

Trial question → protocol written → entry rules defined → treatment schedule defined → monitoring defined → results measured.

The protocol is not a suggestion. It is the set of rules the trial team must follow.

This is why a doctor cannot simply ignore an eligibility rule because the treatment looks suitable for you.

If a rule is unclear, the trial team can interpret how it applies to your case, but they still have to work within the protocol.

Ask: Which protocol rule is most important in deciding whether I can enter this trial?

Investigational does not mean “no evidence”.

It means the treatment, or the way it is being used, is still being tested under a formal research protocol.

The treatment may already have:

laboratory evidence,
animal evidence,
early human safety data,
signs of activity,
or approval in another cancer or treatment setting.

What remains uncertain depends on the trial.

Evidence already exists → important questions remain → treatment is studied formally → more safety and outcome data are collected → the evidence becomes clearer.

Investigational = still being studied.
It does not automatically mean ineffective, unsafe, or completely unknown.

Important: An investigational treatment can still have meaningful uncertainty. Benefit is not guaranteed, and unexpected side effects may still emerge.

Ask: What is already known about this treatment, what is still uncertain, and why might it be relevant to my cancer?

Think of this as the point where a treatment moves from preclinical research into human testing.

Before this point, researchers may already have laboratory and animal evidence.

But the treatment has not yet been tested in people.

Preclinical evidence = what was learned before human treatment.
First-in-human = the first time the treatment is being studied in people.

The earliest questions are often about:

what dose can be given,
what side effects appear,
how the body handles the treatment,
and whether there are early signs of biological or cancer activity.

Laboratory research → preclinical testing → first treatment in people → dose and safety studied → early human evidence begins to build.

Important: First-in-human does not mean there is no scientific reason to study the treatment. It means human evidence is still very limited.

Ask: What has already been learned before this treatment reached people, what is still unknown, and what is this first-in-human study specifically trying to establish?

Think of Phase I as finding the treatment's safe operating range in people.

The trial may study:

what dose can be given,
which side effects appear,
how severe those side effects are,
how the body processes the treatment,
and whether there are early signs that the treatment is affecting the cancer.

Some Phase I trials are also first-in-human studies, but not every Phase I trial is the first time that treatment has ever been given to people.

Treatment enters early human testing → different dose levels may be studied → safety and side effects are measured → biological activity is watched → a dose is selected for further study.

Phase I = early human testing focused heavily on dose and safety.
It can still produce meaningful cancer responses.

Important: In a Phase I trial, more uncertainty may remain about dose, side effects, and the chance of benefit than in later-phase trials.

Ask: What is this Phase I trial mainly trying to establish, what dose would I receive, and what evidence already exists that the treatment may affect my cancer?

Think of Phase II as asking: does this treatment show enough useful activity to justify further study?

The treatment has usually already passed through earlier human testing.

Researchers now look more closely at:

whether tumours shrink,
whether cancer remains controlled,
how long that control lasts,
which patients appear to benefit,
and what side effects continue to occur.

Early dose and safety information exists → more patients receive the treatment → treatment activity is measured → safety continues to be monitored → evidence builds about whether the treatment is worth taking forward.

Phase II = a stronger test of whether the treatment appears to work.

A Phase II trial may still be relatively small and may not always include a direct comparison with another treatment.

Important: A promising Phase II result does not automatically prove that a treatment is better than established care.

Ask: What evidence of benefit is this Phase II trial looking for, and how will the researchers decide whether the treatment is working?

Think of Phase III as the direct comparison stage.

By this point, there is usually already meaningful information about dose, safety, and signs of treatment activity.

The next question is often:

How does this treatment compare with the current treatment approach?

Patients are often placed into different study arms, and the outcomes of those groups are compared.

Earlier evidence looks promising → larger groups are studied → treatments are compared → important outcomes are measured → researchers determine whether the new approach offers a meaningful advantage or other useful difference.

The trial may compare things such as:

tumour response,
progression-free survival,
overall survival,
side effects,
quality of life,
or other defined outcomes.

Phase III = a larger, structured comparison between treatment approaches.

Important: Being in a Phase III trial does not guarantee that you will receive the new treatment. The trial may assign patients to different treatment arms.

Ask: What treatments are being compared, how would I be assigned to an arm, and what outcome is the trial mainly trying to improve?

Think of Phase IV as learning what happens once a treatment moves into much wider use.

Earlier trials may involve carefully selected patients and a more controlled setting.

After a treatment enters routine use, many more people may receive it.

This can reveal things that were difficult to see in smaller earlier studies.

Phase IV can help identify:
longer-term effects,
uncommon side effects,
how the treatment performs in broader patient groups,
and how it is used in routine care.

Treatment enters routine use → more patients receive it → longer-term and broader data accumulate → safety and real-world use become clearer.

Phase IV = learning continues after the treatment has moved into routine use.

Important: Approval or routine use does not mean every question about a treatment has already been answered.

Ask: What is this Phase IV study trying to learn that was not fully answered before the treatment entered routine use?

Think of cancer treatment as the main engine. Integrative care supports the systems that help that engine keep running.

It is used alongside surgery, chemotherapy, radiation, immunotherapy and targeted therapy.

It is not a replacement for them.

Its job is to help protect:

• nutrition
• muscle and strength
• sleep
• physical function
• symptom control
• recovery
• treatment tolerance.

Ask:
“What can I do alongside treatment to protect my ability to keep treating?”

Think of nutrition as both fuel and building material.

Treatment can increase the body's demands at the same time appetite, digestion or absorption becomes harder.

Bile normally reaches the duodenum and helps the body digest and absorb dietary fat.

If bile flow is reduced or blocked, digestion and absorption of fats and fat-soluble nutrients can become more difficult.

Major biliary or pancreatic surgery can also change digestion and nutrient absorption.

That means nutrition support in cholangiocarcinoma is not just about how much food you eat. It can also be about whether the digestive system is able to deliver and absorb that nutrition effectively.

Ask for specialist nutrition support if you are:

• losing weight without trying
• struggling to eat enough
• losing muscle or strength
• having persistent nausea or diarrhoea
• having pale, oily or difficult-to-flush stools
• having trouble digesting food
• recovering from major biliary or pancreatic surgery.

Ask:
“Am I eating enough, and am I absorbing enough nutrition to protect my weight, muscle and ability to tolerate treatment?”

Think of muscle as reserve capacity.

Protecting useful physical reserve can help preserve capacity for treatment, recovery and everyday function.

Exercise needs to match your condition.

Treatment, recent surgery, infection, anaemia, bone problems, falls risk, pain and overall fitness can all change what is appropriate.

Ask:
“What level of movement and strength work is safe for me during treatment?”

Think of sleep as the body's maintenance shift.

Poor sleep can compound fatigue, concentration problems and recovery difficulties.

Sleep can be disrupted by:

• pain
• anxiety
• steroids and other medicines
• nausea
• hospital routines
• treatment side effects
• changes in normal activity.

Ask:
“What is disrupting my sleep, and can that cause be treated directly?”

Think of stress like keeping an engine at high revs.

Continuous load can make sleep, attention and recovery harder.

The aim is not to “think positive”.

It is to identify unnecessary load and reduce what can actually be reduced.

Support may include psychological care, practical help, better symptom control and treatment of sleep problems.

Ask:
“What part of my current load can actually be reduced or better managed?”

Think of side effects as friction.

Enough friction can slow treatment down, force dose changes or stop treatment altogether.

Problems such as:

• nausea and vomiting
• diarrhoea
• constipation
• pain
• fatigue
• neuropathy
• mouth problems
• poor appetite
• sleep disruption

should be reported early rather than simply endured.

Ask:
“Which side effects could threaten my ability to stay on treatment if we do not control them early?”

Think of every supplement as another chemical entering the same system as your treatment.

“Natural” does not automatically mean neutral.

Supplements can affect:

• drug metabolism
• bleeding risk
• liver function
• kidney function
• other medicines
• treatment activity.

This does not mean every supplement is unsafe. It means the interaction needs to be checked.

Keep a complete list of every vitamin, herb, powder, tea, complementary medicine and non-prescription product you use.

Show that list to your treating team or oncology pharmacist.

Ask:
“Does anything I am taking interact with my cancer treatment, liver function or other medicines?”

Think of treatment as dealing with the fire.

Conditions of Cause asks: what was happening in the biological environment that has made the ground easier to burn?

In cholangiocarcinoma, the biological environment of the bile ducts matters.

That means looking first at:

• bile composition
• bile flow
• obstruction or stagnation
• repeated biliary injury
• infection or inflammation within the biliary system.

These conditions can then sit upstream of other biological pressures such as:

• chronic inflammation
• tissue injury
• repeated repair
• metabolic stress
• immune pressure.

Bile has another important job: it must reach the duodenum to help digest and absorb dietary fat.

If bile flow is reduced, blocked or diverted, the downstream digestive system can receive less bile than it needs.

That can impair fat digestion and reduce absorption of fat-soluble nutrients.

Over time, poor digestion, reduced nutrient delivery, weight loss and loss of muscle can add another layer of physiological stress.

This matters during treatment because the patient may be dealing with both the cancer and a digestive system that is less able to deliver the nutrition needed to maintain strength.

It is established that bile flow is important for normal biliary function and for fat digestion and absorption.

It is also established that some chronic biliary conditions and repeated biliary injury increase cholangiocarcinoma risk.

The wider question of exactly how changes in bile composition, bile flow, inflammation, metabolism and immune pressure combine over time to create the conditions in which cholangiocarcinoma develops remains an area of research.

Ask:
“What was happening in my biliary system before this cancer developed, and which biological conditions can still be improved now?”

Think of the treatment plan as one system.

Every new addition should fit into that system rather than compete with it.

Consider any integrative approach in the context of:

• current cancer treatment
• surgery plans
• prescription medicines
• liver function
• kidney function
• bleeding risk
• infection risk
• individual medical conditions.

The question is not simply: “Is this natural?”

The better question is: “Does this strengthen the treatment pathway without creating a new risk?”

Ask:
“Does this approach support my treatment plan, or could it interfere with it?”

Think of palliative care as another layer of care added around you.

Cancer treatment focuses on controlling or removing the cancer.

Palliative care focuses on reducing the burden created by the illness, treatment and its effects on daily life.

This can include help with:

pain, nausea, breathlessness, fatigue, appetite, sleep, bowel problems, emotional distress, practical problems, treatment decisions, family support and planning ahead.

Problem identified → cause considered → symptom or burden treated → function protected → daily life and treatment become easier to manage.

Palliative care = reducing the load.
It does not automatically mean stopping cancer treatment.

Ask: What symptoms, problems or treatment burdens could palliative care help me manage now?

Think of specialist palliative care as bringing in another expert team when the load becomes harder to manage.

The team can include:

palliative care doctors, nurses, GPs, physiotherapists, occupational therapists, psychologists, social workers and other health professionals.

Not every patient needs every member of the team.

The right support depends on the problem that needs solving.

Complex burden identified → specialist team involved → causes and symptoms assessed → care coordinated → treatment adjusted as needs change.

Ask: Would a specialist palliative care team add anything to the support I am already receiving?

Think of it as two teams working on different parts of the same problem.

One team may be treating the cancer with chemotherapy, immunotherapy, targeted therapy, radiation, procedures or another treatment.

The palliative care team can work at the same time to control symptoms, preserve function and reduce treatment burden.

Cancer treatment = acts on the disease.
Palliative care = reduces the burden created by the disease and treatment.

Better symptom control can sometimes make it easier to eat, move, sleep, attend appointments and continue treatment.

Important: Palliative care is not the same thing as a palliative treatment goal. A patient may receive palliative care while the cancer team is still actively treating the disease.

Ask: Can palliative care be added now while my current cancer treatment continues?

Think of palliative care as the larger umbrella.

It can support someone through serious illness for months or sometimes years.

End-of-life care is care for the final phase of life.

Palliative care can begin earlier.
End-of-life care is one part of palliative care.

The same palliative team may provide support at both stages, but the goals and circumstances are different.

Ask: Are you referring me for additional symptom and support care while treatment continues, or are you recommending a change in the overall treatment goal?

Think of a symptom as both a burden and a signal.

Pain, nausea, breathlessness, fatigue, itching, poor appetite or constipation can make daily life and treatment much harder.

Relief matters.

But the next question is: what is causing the symptom?

Symptom appears → immediate burden reduced → cause investigated → reversible problem treated where possible → symptom control adjusted.

For example, severe itching in cholangiocarcinoma may require symptom relief, but impaired bile flow, obstruction or drainage problems may also need assessment.

Treat the symptom.
Look for the cause.
Fix what can be fixed.

Ask: What is causing this symptom, what can relieve it now, and is there an underlying problem we can treat?

Think of serious illness as weight carried by more than one person.

Partners, family members and caregivers may be carrying:

appointments, medicines, transport, meals, symptom monitoring, communication, practical decisions and emotional strain.

Palliative care can help by providing information, counselling, respite, practical support, service coordination and preparation for changes in care.

Caregiver load identified → support needs clarified → services added → practical pressure reduced → patient and family better supported.

Ask: What support is available for the people helping carry this with me?

Think of referral as calling for help while there is still time to use that help.

Referral may be useful when symptoms, treatment side effects, reduced function, emotional distress or practical problems are making daily life harder.

It may also help when treatment choices or future care decisions are becoming more complex.

You do not have to wait until treatment ends.

A GP, oncologist, specialist or another healthcare provider can usually help organise referral.

In some parts of Australia, self-referral may also be possible.

Ask: Would involving palliative care now make treatment or daily life easier to manage?

Think first about what help you need and where you need it.

Palliative care may be delivered:

at home,
in hospital,
through community services,
in a specialist palliative care unit,
in a hospice,
or in residential aged care.

Services and referral pathways vary across Australia.

Need identified → referral requested → local service located → needs assessed → care provided in the most appropriate setting.

Ask: Can you refer me to a palliative care service that can work alongside my cancer team and provide support where I live?

Think of treatment resistance as the cancer finding a way to keep growing despite the treatment.

Resistance can be present from the beginning, or it can develop after a treatment has worked for some time.

Primary resistance = the treatment never controls the cancer well enough.

Acquired resistance = the treatment works first, then the cancer finds a way around it.

Treatment given → cancer initially controlled or not controlled → resistant cancer cells survive or emerge → cancer grows despite treatment → treatment strategy reassessed.

Important: Resistance to one treatment does not mean resistance to every treatment.

Ask: What evidence shows that this cancer is resistant to the current treatment, and what does that tell us about the next treatment?

Think of refractory as a label describing the relationship between the cancer and a particular treatment.

It does not mean that every possible treatment has stopped working.

Refractory to Treatment A does not automatically mean refractory to Treatment B.

Ask: Refractory to which treatment, and what treatment pathways remain open?

The important question is: what was the treatment meant to achieve?

A treatment may be considered unsuccessful because the cancer progressed, because the treatment could not be tolerated, or because it did not achieve the intended treatment goal.

Treatment failure = this treatment did not achieve what it needed to achieve.
It does not equal “nothing else can be done.”

Ask: What exactly failed, what was this treatment meant to achieve, and what options remain?

Think of dose reduction as changing the intensity, not necessarily abandoning the treatment.

Dose may be reduced because of:

side effects,
blood-count changes,
liver or kidney function,
cumulative toxicity,
weight or general health,
or difficulty recovering between cycles.

Treatment given → side effects or tolerance assessed → dose adjusted → treatment continues → response and safety reassessed.

Ask: Why is the dose being reduced, what are we trying to protect, and how will we know whether the reduced dose is still doing what we need it to do?

“Stopped” tells you what happened. It does not tell you why.

Treatment may be discontinued because:

the planned course is complete,
the cancer has progressed,
side effects are too severe,
organ function has changed,
the patient chooses to stop,
or another treatment is considered more appropriate.

Current treatment reviewed → reason for stopping identified → cancer and patient reassessed → remaining options reviewed → next treatment decision made.

Ask: Why exactly is this treatment being stopped, and what does that reason mean for my next options?

Think of reassessment as stopping at the junction before choosing the next road.

Before moving on, the team may need to reconsider:

where the cancer is now,
how it responded to previous treatment,
whether surgery or another local treatment is possible,
whether tumour biology has created a targeted option,
whether a clinical trial is relevant,
and whether the patient is fit for the available choices.

Treatment changes → situation reassessed → opportunities reopened or excluded → next pathway chosen → treatment begins.

Important: Starting another treatment can sometimes change trial eligibility or other future opportunities.

Ask before the next treatment: What has changed, what options should now be reconsidered, and could this next treatment close another opportunity?

“Best supportive care” tells you the focus of part of the care, but it does not always tell you whether cancer-directed treatment is also being given.

Supportive care can include:

pain control,
nausea treatment,
nutrition support,
management of breathlessness,
fatigue,
psychological support,
practical support
and palliative care.

Important: Do not assume that “best supportive care” automatically means there are no cancer-directed treatment options. Clarify what the treating team means in your situation.

Ask: When you say “best supportive care”, are you recommending supportive care alongside active cancer treatment, or are you recommending that cancer-directed treatment stops?

Think of the bile ducts as a branching drainage network.

They carry bile from the liver towards the small intestine.

When cancer begins in the cells lining this bile duct system, it is called cholangiocarcinoma.

Bile duct cancer = cholangiocarcinoma = CCA.

The important next step is to identify exactly where in that network the cancer began.

Bile duct cancer diagnosed → exact starting location identified → anatomical subtype named → surgery and treatment pathways assessed.

Ask: Where exactly in my bile duct system did my cancer begin?

Think of the primary site as the cancer's original address.

If cholangiocarcinoma later spreads to the lung, the cancer in the lung is still cholangiocarcinoma.

It is not automatically a new lung cancer.

Where cancer spreads is not the same thing as where it started.

Ask: What is the confirmed primary site of my cancer?

Picture the bile ducts as small branches running through the liver.

Intrahepatic cholangiocarcinoma begins in those bile ducts inside the liver.

When complete removal is possible, surgery generally involves removing the part of the liver containing the cancer.

Ask: Is my cancer intrahepatic, and has it been assessed for complete surgical removal?

Think of the hilum as the main junction where the right and left liver ducts come together.

Perihilar cholangiocarcinoma begins around this junction.

Surgery can therefore involve:

bile duct removal,
liver resection,
lymph node removal,
and sometimes reconstruction involving nearby blood vessels or bile drainage.

Important: Assessment by a surgeon experienced in perihilar cholangiocarcinoma can be important because operability may depend on specialised surgical expertise.

Ask: Has my cancer been assessed by a surgeon experienced in perihilar cholangiocarcinoma?

Picture the bile duct travelling downward from the liver towards the small intestine.

The distal bile duct is the lower part that passes close to and through the pancreas.

Because the bile duct, pancreas and duodenum are closely connected here, surgery usually requires removal and reconstruction of several connected structures.

Ask: Is my cancer distal cholangiocarcinoma, and has it been assessed for a Whipple procedure?

Extrahepatic simply means outside the liver.

It includes:

perihilar cholangiocarcinoma,
and distal cholangiocarcinoma.

Those two locations have different surgical and treatment pathways.

Ask: Is my extrahepatic cholangiocarcinoma perihilar or distal?

Adenocarcinoma describes what kind of cancer cell the pathologist sees.

It does not by itself tell you where the cancer started.

Adenocarcinoma = cell type.
Cholangiocarcinoma = cancer defined by its origin in the bile duct system.

Ask: Does the pathology confirm adenocarcinoma consistent with a bile duct primary?

Think of differentiation as asking how much the cancer cell still resembles its original normal cell.

Well differentiated = looks more like normal tissue.

Moderately differentiated = sits between the two.

Poorly differentiated = looks much less like normal tissue.

Poorly differentiated cancers may behave more aggressively, but differentiation is only one part of understanding the cancer.

Ask: How differentiated is my tumour, and does that change how you interpret its behaviour?

Think of grade as what the cells look like, and stage as where the cancer is.

Grade = microscopic appearance and expected behaviour.

Stage = how far the cancer has grown or spread.

A tumour can therefore have a particular grade and a completely separate stage.

Ask: What is the tumour grade, and how is that different from my cancer stage?

Think of the stage number as the headline on the map.

The detail underneath that headline matters more when treatment decisions are being made.

Two people can both be called Stage IV while having very different patterns of disease, tumour biology and treatment opportunities.

Stage = summary.
Location = detail.

Cancer identified → extent mapped → stage assigned → actual locations reviewed → treatment pathways assessed.

Ask: What specifically makes my cancer this stage, and exactly where has disease been found?

Think of TNM as three layers of the same map.

T = the main tumour and how far it has grown locally.

N = whether nearby lymph nodes contain cancer.

M = whether distant metastatic disease has been identified.

Main tumour mapped → nodes mapped → distant spread assessed → TNM recorded → overall stage interpreted.

Ask: What are my T, N and M results, and which part is most important to my treatment decision?

Think of T as the local footprint of the main tumour.

A higher T number generally means the tumour has grown further locally.

What each T number means depends on where the cholangiocarcinoma began.

Do not stop at the T number.
Translate it into the actual structures involved.

Ask: What structures make my tumour this T stage, and do any of them prevent curative surgery?

Think of lymph nodes as checkpoints positioned along drainage pathways around the body.

Cancer cells can travel into these nodes.

Not every lymph node has the same staging meaning.

Regional node = nearby in staging terms.
Distant node = metastatic spread.

Ask: Which lymph nodes are involved, and are they considered regional or distant?

M tells you whether distant disease exists.

It does not tell you:

how many sites there are,
how large they are,
where they are,
or whether some can be treated directly.

Ask: Where exactly is the metastatic disease, how many sites are there, and are any local treatment options still relevant?

Think of localised disease as cancer that has stayed in the local neighbourhood.

That does not automatically mean it can be removed.

A tumour can still involve:

blood vessels,
bile ducts,
liver structures,
or nearby organs.

Ask: Has my cancer been assessed directly by a surgeon with high-volume cholangiocarcinoma experience to determine whether it can be completely removed?

Think of locally advanced disease as a local barrier problem.

The tumour may involve a major blood vessel, nearby organ or another structure that currently prevents complete removal.

Local barrier identified → specialist surgical assessment → reconstruction or downstaging considered → operability reassessed.

Ask: What exactly is preventing surgery today, and what would need to change for curative-intent surgery to become possible?

Regional means nearby in staging terms.

The exact definition depends on where the cholangiocarcinoma began.

Regional spread ≠ distant metastasis.

Ask: What part of my disease is considered regional, and does it change whether surgery is possible?

Not every positive lymph node means the same thing.

Nearby regional nodes and distant nodes can affect staging differently.

Positive node identified → exact node location mapped → regional or distant classification made → staging and treatment implications assessed.

Ask: Which lymph nodes are involved, how many are involved, and are they regional or distant?

Think of metastasis as cancer establishing another site away from where it started.

The cancer keeps the identity of its original cancer.

For example, cholangiocarcinoma that has spread to the lung is still cholangiocarcinoma.

New location does not mean new cancer type.

Ask: Where has my cholangiocarcinoma spread, how many metastatic sites are there, and does the pattern create any local treatment opportunity?

Distant metastasis is not one single pattern.

One small metastatic site is different from widespread disease across several organs.

That difference can matter when local treatments such as surgery, radiation, ablation or interventional radiology are considered.

Ask: How many distant metastatic sites do I have, where are they, and can any of them be treated directly?

Think of oligometastatic disease as metastatic disease with only a limited number of visible sites.

In selected patients, treatment may combine whole-body therapy with local treatment directed at individual metastatic sites.

Limited metastatic sites identified → systemic treatment considered → local treatment options reviewed → combined strategy considered where appropriate.

Ask: Is the number and location of my metastatic sites limited enough for surgery, radiation, ablation or another local treatment to be considered?

Think of the peritoneum as the smooth living lining inside the abdomen.

It lines the abdominal cavity and covers the outer surfaces of many abdominal organs.

A small amount of fluid normally sits between these surfaces so organs can move smoothly.

Primary tumour → cancer cells escape → enter the abdominal cavity → move within peritoneal fluid → attach to the lining → survive and multiply → metastatic deposits form.

A report may use terms such as:

peritoneal disease,
peritoneal metastases,
peritoneal deposits,
peritoneal spread,
or peritoneal carcinomatosis.

These terms describe cancer involving the peritoneal lining.

Peritoneal disease can interfere with normal fluid movement and drainage in the abdomen.

This is one reason it can be associated with ascites, which means fluid collecting in the abdomen.

Important: Peritoneal disease and ascites are related concepts, but they are not the same thing.

Peritoneal disease also does not by itself tell you how extensive the cancer is.

A small number of deposits and widespread peritoneal involvement are different clinical pictures.

Ask: Where is the peritoneal disease, how extensive is it, is it causing ascites or another problem, and does the pattern create any treatment or specialist procedural option?

Think of CT as taking the body and viewing it in thin internal slices.

Those slices can be reconstructed so the radiologist can examine:

tumour size,
tumour location,
blood vessels,
nearby organs,
lymph nodes,
and possible metastatic sites.

X-ray images collected → computer reconstructs body slices → radiologist maps abnormal areas → findings compared → treatment implications assessed.

Ask: What was this CT intended to answer, and what did it show that changes my treatment plan?

Think of MRI as a camera especially good at separating different types of soft tissue.

In cholangiocarcinoma, this can help define:

liver lesions,
bile duct involvement,
blood vessel relationships,
and the extent of disease around the primary tumour.

Ask: What did the MRI clarify that was not clear on my other imaging?

Think of MRCP as creating a map of the bile duct plumbing.

Unlike ERCP, MRCP creates images without placing an endoscope into the bile ducts.

MRI performed → fluid-filled ducts highlighted → narrowing or obstruction mapped → extent along duct system assessed → drainage or treatment planning informed.

MRCP = imaging.
ERCP can also be used to intervene in the bile ducts.

Ask: Where is the narrowing or blockage, and how far does it extend along the bile duct system?

PET is not simply a camera looking for tumour shape.

It is looking at where the tracer accumulates.

Many PET scans use a tracer related to glucose metabolism.

Important: Increased uptake does not automatically mean cancer. Inflammation, infection and some normal tissues can also take up tracer.

Not every cholangiocarcinoma shows strongly on PET, so PET findings are interpreted with CT, MRI and the wider clinical picture.

Ask: What areas showed abnormal uptake, and do those findings change my stage or treatment options?

Think of ultrasound as using echoes to build an image.

It can help assess:

bile duct dilation,
gallbladder changes,
liver abnormalities,
blood flow in some settings,
and fluid such as ascites.

Ultrasound can also be used to guide some procedures, including drainage and biopsy.

Ask: What abnormality was the ultrasound trying to confirm, and does it require another scan or procedure?

Think of contrast as temporarily increasing the difference between structures in the image.

Some tissues take up contrast quickly. Others take it up slowly or appear differently at different scan phases.

Contrast does not create the abnormality.
It helps make differences easier to see.

Ask: Was contrast used, and did the contrast pattern help clarify what the abnormal area is?

Think of “lesion” as the radiologist saying: “There is an area here that looks different.”

What that area represents depends on:

its appearance,
location,
size,
contrast behaviour,
change over time,
and sometimes pathology.

Ask: What does this lesion most likely represent, and what evidence supports that interpretation?

Mass describes shape or presence, not necessarily cause.

The radiologist may use other features to judge whether a mass looks suspicious for cancer.

Mass = something is there.
Diagnosis = what that something is.

Ask: Is this mass believed to be cancer, and what makes the team confident about that interpretation?

Think of enhancement as the tissue becoming more visible after contrast arrives.

Different tissues receive and retain contrast in different ways.

Enhancement is a clue.
It is not by itself a cancer diagnosis.

Ask: What does the enhancement pattern suggest about this area, and is further investigation needed?

Uptake means tracer collected there.

It does not automatically tell you why it collected there.